Korean Govt to Temporarily Exempt Tamiflu, Relenza from Tariffs; Green Cross Begins H1N1 Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The Korean government will temporarily exempt Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) from a tariff and a local value-added tax until the end of next year as part of an effort to help local A/H1N1 flu patients get fast and easy access to treatments at lower costs